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Tumor suppressor p53 and its signaling pathway play a central role in tumor prevention. The E3 ubiquitin ligase 
MDM2, which is a direct p53 transcriptional target and also the most critical negative regulator of p53, forms an 
autoregulatory negative feedback loop with p53 in the cell to tightly regulate the levels and activity of p53. 
MicroRNAs (miRNAs) are endogenously expressed small non-coding RNAs that play a critical role in the 
post-translational regulation of gene expression. Recent studies have revealed that miRNAs directly regulate the 
levels of p53 or MDM2 to modulate the p53 function in tumor suppression. Recently, we identified miR-339-5p 
as a new miRNA that directly represses MDM2 to activate p53 and enhance p53 function in tumor suppression. 
Thus, miRNAs have become a new but important component of the p53 signaling pathway through regulating 
the p53/MDM2 feedback loop. 
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Tumor suppressor p53 and its signaling pathway play a 
central role in tumor prevention [1-3]. p53 is a transcription 
factor, and exerts its tumor suppressive function mainly 
through regulation of the expression of many downstream 
target genes.  In response to stress signals, p53 selectively 
regulates its target genes to initiate a wide variety of cellular 
responses, including cell cycle arrest, senescence, DNA 
repair, and apoptosis, depending on the type of cells, the type 
and degree of stress signals, and environmental contexts as 
well [1-3]. Through these cellular responses, p53 prevents the 
propagation of damaged and mutant cells that could 
potentially give rise to tumors. The p53 gene is mutated in 
almost every type of cancer and over half of all cancers, 
which makes p53 the most frequently-mutated gene in 
human cancer. In addition to DNA mutations, p53 is 
frequently inactivated by different mechanisms in cancer. For 
instance, p53 is frequently inactivated by the DNA 
amplification and/or overexpression of its negative regulator 
MDM2 in many types of tumors, such as sarcoma, breast 
cancer and colorectal cancer [4, 5]. MDM2 is a direct 
transcriptional target of p53. p53 binds to the p53 consensus 
DNA binding sequences in the promoter region of MDM2, 
and transcriptionally induces MDM2 expression under both 
non-stressed and stressed conditions. In turn, as an E3 
ubiquitin ligase, MDM2 is the most critical negative 
regulator of p53. MDM2 binds to p53 and ubiquitinates p53 
to promote its degradation [6, 7]. Thus, p53 and MDM2 form 
an autoregulatory negative feedback loop in the cell to 
maintain the balance between p53 and MDM2, which is 
critical for the p53 function in tumor suppression [6, 7]. The 
disruption of the balance between p53 and MDM2 by the 
MDM2 amplification and/or overexpression in cancer 
impairs the function of p53 in tumor suppression, which 
constitutes an important mechanism for p53 inactivation in 
cancer to promote tumorigenesis [3, 6]. 
MicroRNAs (miRNAs) are endogenously expressed small 
non-coding RNAs which play a critical role in the regulation 
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of gene expression in the cell [8, 9].  miRNAs bind to the 
partially complementary sites in the 3′-UTRs of specific 
mRNAs to inhibit the translation and/or induce the 
degradation of these mRNAs, and thereby regulate the 
expression of genes at the post-transcriptional level.  
miRNAs are involved in the regulation of a wide variety of 
critical biological processes, such as development and 
differentiation, cell growth and proliferation, cell death and 
survival, metabolism, etc [8, 9]. These biological processes are 
often perturbed in cancer, which contributes to 
tumorigenesis. It has been well-documented that the 
expression patterns of many miRNAs are often altered in 
various types of cancer, which leads to the perturbation of 
above-mentioned biological processes and thereby 
contributes to tumorigenesis [10, 11]. Through the negative 
regulation of the expression of many different oncogenes and 
tumor suppressor genes, miRNAs have been demonstrated to 
function as either tumor suppressors or oncomiRs in cancer 
[10, 11].  
Recent studies have demonstrated that miRNAs play an 
important role in regulating the p53 function in tumor 
suppression through regulating the balance between p53 and 
MDM2. So far, over 20 miRNAs have been identified as the 
direct negative regulators of p53 through binding to 3’-UTR 
of the p53 mRNA, including miR-125b, miR-504, 
miR-380-5p, miR-1285, miR-92, miR-141, miR-25, miR-33, 
miR-98, miR-453, miR-15a, miR-16, etc [12-15]. Among them, 
miR-125b and miR-504 were the first group of miRNAs that 
were identified to directly target p53 [16, 17]. The miR-125b 
was first reported to reduce p53 protein levels and impair 
p53-induced apoptosis in human cells and the brain of 
zebrafish [16]. Our previous study reported that miR-504 
directly reduces the p53 protein levels and therefore 
negatively regulates p53-mediated apoptosis and cell cycle 
arrest in cancer cells. Furthermore, overexpression of 
miR-504 promotes the tumorigenicity of colorectal cancer 
cells in xenograft tumor models in vivo in a largely 
p53-dependent manner [17]. In addition to miR-125b and 
miR-504, many other miRNAs that directly target p53 were 
reported to promote cancer cell proliferation through 
repressing the p53 mediated-apoptosis, cell cycle arrest 
and/or senescence [12, 18-20]. Many of these miRNAs have 
been reported to be overexpressed in different types of 
cancer, which can directly repress the p53 protein levels to 
impair the tumor suppressive function of p53 [12, 18, 19].  
In addition to the above-mentioned miRNAs that directly 
repress p53, a group of miRNAs has been identified to 
activate p53 by directly repressing MDM2, such as miR-192, 
miR-194, miR-215, miR-605, miR-25, miR-32, miR-17-3p, 
miR-143, miR-145, miR-661, miR-660, etc [12, 18, 21]. Almost 
all of these miRNAs have been demonstrated to be able to 
inhibit cancer cell proliferation through promoting the 
p53-mediated apoptosis, cell cycle arrest and/or senescence 
[12, 18, 21]. Some of them were also reported to repress the 
migration and invasion of cancer cells and reverse 
epithelial-mesenchymal-transition (EMT) to inhibit cancer 
metastasis [22, 23]. Interestingly, some of these miRNAs, such 
as miR192, miR-194, miR-215, miR-605, miR-143 and 
miR-145, were also identified to be the transcriptional targets 
of p53. These miRNAs form positive feedback loops with 
p53 and help to activate p53 especially under the condition of 
stress [12, 18, 21].  
Recently, we identified miR-339-5p as an additional 
miRNA that activates p53 through directly binding to the 
3’-UTR of MDM2 mRNA [24]. We found that miR-339-5p 
reduces the MDM2 protein levels to increase p53 protein 
levels, leading to the enhanced p53 functions in inducing 
apoptosis and senescence and inhibiting cell migration and 
invasion as well. MiR-339-5p also represses the growth of 
colorectal xenograft tumors in mice through p53 activation 
[24]. MiR-339-5p has been reported to be frequently 
down-regulated in different types of cancers, such as 
colorectal, breast and lung cancers [25-27]. Furthermore, the 
down-regulation of miR-339-5p was reported to be 
associated with cancer metastasis and poor prognosis in 
cancer patients [25-27]. Consistent with our findings, a recent 
study from another group also reported that MDM2 is a 
direct target for miR-339-5p [28]. Furthermore, they found a 
negative correlation between miR-339-5p and MDM2 
expression in both human colorectal cancer and renal 
clear-cell carcinoma [28]. These studies together indicate an 
important role of miR-339-5p in tumor suppression through 
its regulation of the p53/MDM2 negative feedback loop. 
In addition to the regulation of p53 or MDM2 by 
miRNAs, recent studies have also demonstrated that p53 can 
either induce or repress the expression of many different 
miRNAs, which in turn function as mediators for p53 in 
tumor suppression [12, 18-20]. Thus, through regulating the p53 
levels or mediating the p53 function in tumor suppression, 
miRNAs have become a new but important component of the 
p53 signaling pathway.  
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